0.3162
Precedente Chiudi:
$0.325
Aprire:
$0.3183
Volume 24 ore:
125.73K
Relative Volume:
0.43
Capitalizzazione di mercato:
$12.13M
Reddito:
$7.88M
Utile/perdita netta:
$-69.20M
Rapporto P/E:
-0.1728
EPS:
-1.83
Flusso di cassa netto:
$-69.73M
1 W Prestazione:
+7.90%
1M Prestazione:
-15.01%
6M Prestazione:
-45.36%
1 anno Prestazione:
-59.18%
Bolt Biotherapeutics Inc Stock (BOLT) Company Profile
Nome
Bolt Biotherapeutics Inc
Settore
Industria
Telefono
650-665-9295
Indirizzo
900 CHESAPEAKE DRIVE, REDWOOD CITY
Confronta BOLT con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
BOLT
Bolt Biotherapeutics Inc
|
0.3163 | 12.15M | 7.88M | -69.20M | -69.73M | -1.83 |
![]()
ONC
Beigene Ltd Adr
|
241.78 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
434.56 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.31 | 42.47M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
587.75 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
74.98 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Bolt Biotherapeutics Inc Stock (BOLT) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2021-03-02 | Iniziato | Guggenheim | Buy |
2021-03-02 | Iniziato | Morgan Stanley | Overweight |
2021-03-02 | Iniziato | SVB Leerink | Outperform |
2021-03-02 | Iniziato | Stifel | Buy |
Bolt Biotherapeutics Inc Borsa (BOLT) Ultime notizie
Lake Street Capital Begins Coverage on Bolt Biotherapeutics (NASDAQ:BOLT) - Defense World
Lake Street Initiates Coverage of Bolt Biotherapeutics (BOLT) with Buy Recommendation - Nasdaq
BOLT: Lake Street Initiates Coverage on Bolt Biotherapeutics wit - GuruFocus
BOLT: Lake Street Initiates Coverage on Bolt Biotherapeutics with Buy Rating | BOLT Stock News - GuruFocus
Lake Street Begins Coverage of Bolt Biotherapeutics (BOLT) with Bullish Outlook | BOLT Stock News - GuruFocus
Leerink Partnrs Has Optimistic Outlook of BOLT Q2 Earnings - Defense World
Stifel Nicolaus Lowers Bolt Biotherapeutics (NASDAQ:BOLT) Price Target to $1.00 - Defense World
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates - MSN
BOLT Stock Target Price Revised to $1 Amid Recent Developments | - GuruFocus
BOLT: Stifel Lowers Price Target on Bolt Biotherapeutics, Mainta - GuruFocus
Bolt Biotherapeutics Reports Q1 2025 Financial Results - TipRanks
BOLT Exceeds Q1 Revenue Expectations with Higher Earnings | BOLT Stock News - GuruFocus
Bolt Biotherapeutics Inc.: Q1 Earnings Snapshot - San Antonio Express-News
Bolt Biotherapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Bolt Biotherapeutics Inc (BOLT) Q1 2025 Earnings: EPS of -$0.29 - GuruFocus
Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Bolt Biotherapeutics, Inc. SEC 10-Q Report - TradingView
Bolt Biotherapeutics (BOLT) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
BOLT: Surge in Interest for Bolt Biotherapeutics Amid Key Develo - GuruFocus
Bolt Biotherapeutics (BOLT) to Host Webcast on Clinical Study an - GuruFocus
Bolt Biotherapeutics (BOLT) to Host Webcast on Clinical Study and Financial Updates | BOLT Stock News - GuruFocus
Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates - The Manila Times
Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 ... - Eagle-Tribune
Bolt Biotherapeutics, Inc. (BOLT) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates - ACCESS Newswire
Bolt Biotherapeutics amends bylaws, adjusts quorum requirement - Investing.com Australia
Innovative Advances in Bolt Biotherapeutics (BOLT) Cancer Therap - GuruFocus
Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025 - The Manila Times
Bolt Biotherapeutics amends bylaws, adjusts quorum requirement By Investing.com - Investing.com India
Press Release Distribution & PR Platform - ACCESS Newswire
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - The Manila Times
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Esca - GuruFocus
Bolt Biotherapeutics reports positive Phase 1 cancer trial results By Investing.com - Investing.com India
Bolt Biotherapeutics Reports Positive Phase 1 Results for BDC-3042, Demonstrating Safety and Anti-Tumor Activity in Cancer Patients - Nasdaq
Breakthrough Cancer Drug Achieves 80% Disease Control: Phase 1 Trial Reveals Promising NSCLC Results - Stock Titan
Bolt Biotherapeutics modifies quorum requirements By Investing.com - Investing.com Canada
Bolt Biotherapeutics modifies quorum requirements - Investing.com
BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit - marketscreener.com
BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Sept. 3rd Deadline ALERT: Investors Who Lost More Than $100,000 With Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Shares Should Contact the Shareholders Foundation - ACCESS Newswire
BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Bolt Biotherapeutics, Inc. (BOLT) - ACCESS Newswire
Bolt Biotherapeutics stock hits 52-week low at $0.38 By Investing.com - Investing.com UK
BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
What is HC Wainwright’s Estimate for BOLT Q1 Earnings? - Defense World
What is Leerink Partnrs’ Forecast for BOLT Q1 Earnings? - Defense World
Q3 Earnings Forecast for BOLT Issued By HC Wainwright - Defense World
Bolt Biotherapeutics Inc Azioni (BOLT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):